Advertisement
Canada markets close in 28 minutes

  • S&P/TSX

    21,785.06
    +76.62 (+0.35%)
     

  • S&P 500

    4,965.37
    -45.75 (-0.91%)
     

  • DOW

    37,949.12
    +173.74 (+0.46%)
     

  • CAD/USD

    0.7273
    +0.0009 (+0.13%)
     

  • CRUDE OIL

    83.30
    +0.57 (+0.69%)
     

  • Bitcoin CAD

    88,511.54
    +1,479.56 (+1.70%)
     

  • CMC Crypto 200

    1,382.83
    +70.21 (+5.35%)
     

  • GOLD FUTURES

    2,409.20
    +11.20 (+0.47%)
     

  • RUSSELL 2000

    1,938.98
    -3.98 (-0.20%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,279.06
    -322.44 (-2.07%)
     

  • VOLATILITY

    19.02
    +1.02 (+5.67%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Stocks in play: Emerald Health Therapeutics, Inc.

Baystreet.ca

Announced that its Québec facility, Verdélite, has received its Standard Processing License from Health Canada. This license means that, in addition to Verdélite’s right to cultivate and sell cannabis flowers, it can now extract, manufacture, synthesize, test and sell next-generation cannabis products and will position Verdélite to launch these products in conjunction with the expected legalization of a broader spectrum of cannabis products in Canada in October 2019. The license also allows Verdélite to build and operate a laboratory for research and development of cannabis-based products. Emerald Health Therapeutics, Inc. shares V.EMH are trading up $0.01 at $4.29.